Nabi Biopharmaceuticals : Announces Third Quarter 2011 Financial Results Release Date
10/26/2011| 09:21am US/Eastern
Recommend:
ROCKVILLE, Md., Oct 26, 2011 (GlobeNewswire via COMTEX) --
Nabi Biopharmaceuticals (Nasdaq:NABI) will report its third
quarter 2011 financial results on Wednesday, November 2,
2011, after the market close. The company will host a live
webcast at 4:30 p.m. EDT that day to discuss these results.
The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=4220891
Due to the length of this URL, it may be necessary to copy
and paste this hyperlink into your browser. The webcast is
also available via the Nabi Biopharmaceuticals website at
http://www.nabi.com.
If you do not have Internet access, the U.S./Canada call-in
number is 800-261-3417 and the international call-in number
is 617-614-3673. The passcode is 44549064. An audio replay
will be available through November 9, 2011 for U.S./Canada
callers at 888-286-8010 and for international callers at
617-801-6888. The replay passcode is 42793625.
The press release and an archived version of the webcast will
be available on the company's website at
http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and
knowledge in powering the immune system to develop products
that target serious medical conditions in the areas of
nicotine addiction and gram-positive bacterial infections.
Nabi Biopharmaceuticals is currently developing NicVAX(R)
(Nicotine Conjugate Vaccine), an innovative and proprietary
investigational vaccine for treatment of nicotine addiction
and prevention of smoking relapse. The company is
headquartered in Rockville, Maryland. For additional
information about Nabi Biopharmaceuticals, please visit
www.nabi.
This news release was distributed by GlobeNewswire,
www.globenewswire.
SOURCE: Nabi Biopharmaceuticals
CONTACT: Investor Relations
301-770-3099 | www.nabi.
Recommend :
